Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Emily S. Van Laar"'
Autor:
Farrukh T. Awan, Patrick Kugel, Katie S. Lucero, Lauren Willis, Jacqueline C. Barrientos, John N. Allan, Emily S Van Laar, Lisa Brauer, Danielle M. Brander, Jonathon B. Cohen
Publikováno v:
Blood. 134:5878-5878
Introduction: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western world. Treatment selection in CLL is dependent upon a number of factors, such as patient age and genetic mutations, and can be challenging. A number of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a160c9097edb3d62b8e5e4a88b0bd223
https://doi.org/10.1182/blood-2019-124808
https://doi.org/10.1182/blood-2019-124808
Autor:
Jeremy Webber, John R. MacDonald, Emily S. Van Laar, Yan Zhang, Kevin H. Mayo, Ruud P.M. Dings, Robert J. Griffin, Stephen J. Waters
Publikováno v:
Cancer Letters. 265:270-280
Combination of chemotherapeutic agents and angiogenesis inhibitors is now commonly employed in the clinic to treat cancer. Here, we used angiostatic agents anginex and 0118, in combination with the chemotherapeutic irofulven, to treat human ovarian t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb2d5890b42c83c9112be20aa886a6e6
https://doi.org/10.1016/j.canlet.2008.02.048
https://doi.org/10.1016/j.canlet.2008.02.048
Purpose Because as many as 30 % of cancer patients who receive chemotherapy of moderate or high emetogenic potential suffer from chemotherapy-induced nausea and vomiting (CINV), we undertook a multinational survey to identify health care providers’
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a98ee51de9e73dc7a23cdaa451d0f12
https://europepmc.org/articles/PMC4291310/
https://europepmc.org/articles/PMC4291310/
Autor:
Florence Koeppel, Esteban Cvitkovic, Eric Raymond, Maria Serova, Annette K. Larsen, Stephen J. Waters, Fabien Calvo, Emily S. Van Laar, François Lokiec, V. Poindessous
Publikováno v:
Cancer Chemotherapy and Pharmacology. 57:491-499
Purpose: This study assessed the cytotoxic effects of irofulven in combination with oxaliplatin and cisplatin in a panel of human cancer cell lines. Methods: Growth inhibition studies were performed using the human HT29 colon cancer cell line, iroful
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::850071870c8b138aacf07599a40b1e0f
https://doi.org/10.1007/s00280-005-0063-y
https://doi.org/10.1007/s00280-005-0063-y
Autor:
Emily S. Van Laar, Ruud P.M. Dings, Yan Zhang, John R. MacDonald, Kevin H. Mayo, Stephen J. Waters, Melissa L. Loren, Jeremy Webber
Publikováno v:
Bioconjugate chemistry. 21(1)
Targeted delivery of therapeutic drugs promises to become the norm to treat cancer. Here, we conjugated the cytotoxic agent 6-hydroxypropylacylfulvene (HPAF) to anginex, a peptide that targets galectin-1, which is highly expressed in endothelial cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78d4bcb9dd5144c338ec7297a45d05b5
https://pubmed.ncbi.nlm.nih.gov/20020769
https://pubmed.ncbi.nlm.nih.gov/20020769
Autor:
Sujata Arora, David P. Steensma, Julie C. Porcher, William J. Hogan, Mark R. Litzow, Emily S. Van Laar
Treatment with one of the DNA methyltransferase inhibitors (DNMTIs, “hypomethylating agents”), azacitidine or decitabine, is now considered standard care for patients with higherrisk myelodysplastic syndromes (MDS) (1) – especially since result
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83728fbe53a07d0d17a81a3a00136224
https://europepmc.org/articles/PMC2730658/
https://europepmc.org/articles/PMC2730658/
Autor:
Emily S Van Laar, Ola Landgren
Publikováno v:
Blood. 126:3320-3320
Driven by ever-increasing access to diagnostic/prognostic tools and new therapies, the treatment and management of multiple myeloma (MM) is rapidly evolving. This in turn leads to a direct clinical need for updated, timely, and effective education ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9744194dac914234eb5f71a318791e06
https://doi.org/10.1182/blood.v126.23.3320.3320
https://doi.org/10.1182/blood.v126.23.3320.3320
Autor:
John Maeglin, Steven W. Pipe, Mila Kostic, Charlotte Warren, Emily S Van Laar, Michael Schoen, Neil Frick
Publikováno v:
Blood. 126:5593-5593
The field of hemophilia has advanced tremendously over the past few decades leading to significant improvements to a patient's life expectancy. However, gaps in clinician's knowledge about appropriate tailored management of hemophilia can result in s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e1f5ded77fa1d498ba0e5edf7b29b8c
https://doi.org/10.1182/blood.v126.23.5593.5593
https://doi.org/10.1182/blood.v126.23.5593.5593
Publikováno v:
Supportive Care in Cancer. 23:2213-2213
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cf989b633e6e8f657bf4c4023f04f0a
https://doi.org/10.1007/s00520-015-2753-2
https://doi.org/10.1007/s00520-015-2753-2
Autor:
Stephen J. Waters, Jian Wang, Carmenza Mikell, Yutian Wang, Timothy Wiltshire, Weixin Wang, Emily S. Van Laar, Cynthia Cunningham, Eddie Reed, Julian Burks
Publikováno v:
The Journal of biological chemistry. 279(38)
Irofulven (6-hydroxymethylacylfulvene, HMAF, MGI 114) is one of a new class of anticancer agents that are semisynthetic derivatives of the mushroom toxin illudin S. Preclinical studies and clinical trials have demonstrated that irofulven is effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87d74ab11af2c9bf442a079e388aa16d
https://pubmed.ncbi.nlm.nih.gov/15269203
https://pubmed.ncbi.nlm.nih.gov/15269203